Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $31,100.85 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total value of $11,784.75.
• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total value of $11,460.00.

Becton, Dickinson and Company Trading Up 0.8%

BDX stock opened at $189.71 on Friday. The company has a market capitalization of $52.27 billion, a PE ratio of 57.14, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company’s 50 day moving average price is $166.14 and its two-hundred day moving average price is $160.53.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $25,000. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth about $26,000. Meeder Asset Management Inc. boosted its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $29,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of analyst reports. The Goldman Sachs Group dropped their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective on the stock. Finally, Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.